Philip Rosen Patient Friend

Phil first learned about the MMRF Road to Victories event last fall when he accompanied his wife to Vermont for her participation. He met many of the R2V Team members and staff and knew that he wanted to be a part of this incredible event.

Later that fall Phil learned that his co-worker, Tom Fadden, CFO, for Haughn Insurance had been diagnosed with Multiple Myeloma.  Phil is riding to support and honor Tom’s incredible spirit as he battles his MM with positivity and a great sense of humor.

As an avid cyclist for more than 30 years Phil has been involved in supporting various causes in his community. He coached for The Leukemia and Lymphoma Society’s Team in Training program for 5 seasons and serves on The Pedal with Pete Foundation Board, supporting Cerebral Palsy research.  Training for the challenges of the Columbia River Valley Gorge and fundraising for MMRF to support research for Multiple Myeloma and patient support are a mission he is pursuing with great passion and determination.

Sorry, there are no posts from this member.
The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. Learn more and sign up to receive news and resources from the MMRF.

Learn More

At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Janssen Oncology

Click below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.

Learn More